Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGEM vs MPLT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

CGEM Overall Winner 6-Pillar Tally: CGEM 3 – 2 MPLT (1 Tie) Matrix Metrics: CGEM 5 – 2 MPLT

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEM carries a Unified Composite Score of 48.4/100 (HOLD) at $9.72 (6.7x Forward P/E, 0.0% operating margin), whereas MPLT carries 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MPLT currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. CGEM 48.4/100 HOLD), CGEM captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEM vs MPLT
CGEM NASDAQ Head-to-Head Winner
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.56β · 104% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $13.22 · SMA50: $15.63
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap $392.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 78% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 64.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $7.44 · SMA50: $9.21

6-Pillar Scorecard Institutional Category Breakdown (CGEM 3 – 2 MPLT)

Columns: Metric · CGEM · MPLT
1. Valuation Multiples CGEM
Forward P/E 6.7x N/M
Trailing P/E 6.7x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CGEM
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $653.8M $392.9M
3. Profitability & Quality CGEM
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -50.3% -111.5%
4. Balance Sheet & Cash Flow MPLT
Cash Generation (TTM) N/A -$175M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.33 Book/Sh · -50.3% ROE $70M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MPLT
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 124.5% (9th %ile) 92.5% (8th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEM (5) vs MPLT (2)
Institutional Metric CGEM MPLT Criterion Row Edge
Market Capitalization
Scale
$653.8M $392.9M Larger Scale CGEM
Trailing P/E Ratio
Valuation
6.7x N/M Lower Multiple CGEM
Forward P/E Ratio
Valuation
6.7x N/M Lower Multiple CGEM
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-50.3% -111.5% Higher ROE CGEM
52-Week Range Position
Momentum
12% ($8–$23) 3% ($6–$40) Stronger Trend CGEM
Beta / 30D Volatility
Risk Regime
1.56β · 104% Vol 1.05β · 78% Vol Lower Realized Risk MPLT
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite MPLT
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.33 Book/Sh · -50.3% ROE) -$175M ($70M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MPLT +14.96 pp
CGEM: -24.83% · MPLT: -9.87%
3M Horizon MPLT +12.07 pp
CGEM: -53.36% · MPLT: -41.29%
6M Horizon CGEM +39.18 pp
CGEM: -34.63% · MPLT: -73.81%
1Y Horizon CGEM +68.93 pp
CGEM: +17.53% · MPLT: -51.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs MPLT. Trailing 12-month operating profitability (CGEM 0.0% vs MPLT 0.0%) and valuation multiples (CGEM 6.7x vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-50.3% · 6.7x
MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-111.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MPLT BREAKDOWN
144d in phase · OBV ACCUMULATION
Current IV 92.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $653.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $392.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CGEM vs MPLT Key Questions & Quantitative Answers

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEM carries a Unified Composite Score of 48.4/100 (HOLD) at $9.72 (6.7x Forward P/E, 0.0% operating margin), whereas MPLT carries 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MPLT currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. CGEM 48.4/100 HOLD), CGEM captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEM leads the Growth & Scale pillar: CGEM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CGEM generates N/A in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, CGEM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.

CGEM screens cheaper on headline valuation multiples. CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEM (-50.3% ROE) versus MPLT (-111.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 104% Vol realized risk). By comparison, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.